PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Public ClinicalTrials.gov record NCT03365791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Study identification
- NCT ID
- NCT03365791
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Not listed
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2018
- Primary completion
- Feb 20, 2019
- Completion
- Sep 16, 2020
- Last update posted
- May 26, 2022
2018 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Pacific Medical Center Drug Shipment (2) | San Francisco | California | 94120-7999 | — |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| University Cancer and Blood Center, LLC | Athens | Georgia | 30607 | — |
| Northwestern University Medical School | Chicago | Illinois | 60611 | — |
| University of Illinois Cancer Center at Chicago SC | Chicago | Illinois | 60612 | — |
| Illinois Cancer Care P.C. Jesse Brown VA | Peoria | Illinois | 61615-7828 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| University of Iowa Hospitals and Clinics Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| The University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| Weinberg Cancer Institute at Franklin Square Hospital | Baltimore | Maryland | 21237-3998 | — |
| Billings Clinic Dept of Billings Clinic(2) | Billings | Montana | 59101 | — |
| Oncology Hematology West Nebraska Cancer Specialists | Omaha | Nebraska | 68124 | — |
| Comprehensive Cancer Centers | Las Vegas | Nevada | 89169 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Oncology Consultants Oncology Consultants | Houston | Texas | 77024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03365791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2022 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03365791 live on ClinicalTrials.gov.